Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q1 2024 · 10-Q
Revenue$10.01M$10.01M+4,327.9% vs Q1 2023 Net Income-$81.39M-$81.39MN/M vs Q1 2023 EPS Diluted-$0.62-$0.62N/M vs Q1 2023 Operating Income-$90,363,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
Free Cash Flowderived-$52,103,000N/M Margins · derivedOperating margin-903.0%+43865.6 pt vs Q1 2023
Net margin-813.3%+40885.4 pt vs Q1 2023
ended Mar 31, 2024 · filed May 2, 2024 · 32 d after period end